QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: Topical Bovine Thrombin, Haemostasis, Immunogenicity and Pharmacovigilance

Test your understanding of the concepts covered by Topical Bovine Thrombin: Haemostasis, Immunogenicity and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which exposure data set would provide the strongest foundation for a pharmacovigilance assessment of topical bovine thrombin?

Procedure, anatomical site, product presentation, lot, application method, reconstituted concentration and prior exposure Only the patient's discharge diagnosis Only the generic term 'topical haemostatic agent' Only the date of hospital admission

Question 2 of 10 What is the principal haemostatic action of topical thrombin?

It converts fibrinogen into fibrin at the bleeding surface It dissolves fibrin and reopens obstructed vessels It blocks platelet adhesion throughout the circulation It replaces deficient human factor V systemically

Question 3 of 10 How can antibodies generated after bovine thrombin exposure produce severe bleeding?

They may neutralize human factor V and impair thrombin generation They directly dissolve all fibrin at the original surgical site They permanently inhibit platelet production in the bone marrow They convert human thrombin into an anticoagulant

Question 4 of 10 What governance control is most relevant when a new liquid presentation of the product becomes available?

Update product dictionaries, training and error surveillance while retaining the core immunogenicity controls Treat the new presentation as a completely unrelated active substance Remove the existing powder presentation from all historical safety records Stop collecting lot and presentation information because the formulation is liquid

Question 5 of 10 Which statement best captures the central pharmacovigilance relationship described in the article?

Remote bovine thrombin exposure can lead to antibody formation, cross-reaction with human coagulation proteins and later bleeding or thrombosis Local haemostatic benefit prevents any possibility of delayed systemic adverse reactions Only immediate local irritation is biologically plausible after topical application A later coagulation disorder can be assessed without knowing the patient's prior surgical exposures

Question 6 of 10 An institution's medication history contains no record of topical haemostatic agents, but the operating-room record is incomplete. What system improvement would most directly reduce the risk of missed bovine thrombin exposure?

Integrate operative-record review and theatre product documentation into the pharmacovigilance process Rely exclusively on patient recall during follow-up Remove topical products from medication reconciliation workflows Limit case review to products prescribed at hospital discharge

Question 7 of 10 Why does topical administration bypass part of the normal coagulation cascade?

It supplies active thrombin directly at the site requiring fibrin formation It permanently activates every coagulation factor in the patient's plasma It prevents the liver from producing anticoagulant proteins It converts human factor V into bovine factor V

Question 8 of 10 Which information is most appropriate for characterizing a suspected immediate hypersensitivity reaction?

Timing, affected organ systems, treatment, outcome and any prior bovine thrombin exposure Only the indication for surgery Only the product lot number, without clinical details Only whether postoperative bleeding also occurred

Question 9 of 10 Which information is most important when assessing a product complaint involving a reconstituted powder presentation?

The reconstitution process, resulting concentration and whether the preparation contributed to a dosing or administration error Only the patient's age, without details of product handling Only the colour of the operating-room walls Whether the patient had ever used an oral analgesic

Question 10 of 10 How should a wrong-route event involving injection of topical bovine thrombin be managed from a pharmacovigilance perspective?

As a serious medication error requiring escalation and assessment for potential systemic harm, even if no immediate event is reported As a routine product complaint with no safety relevance if the patient is initially well As evidence that the product was used correctly because it entered the body Only as an efficacy issue concerning control of surgical bleeding

Knowledge Assessment: Topical Bovine Thrombin, Haemostasis, Immunogenicity and Pharmacovigilance

Cookie Settings